Abstract
ObjectiveTo determine whether the combined use of glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT-2) inhibitors is associated with a decreased risk of major adverse cardiovascular events and serious...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have